Literature DB >> 17277133

CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors.

Anton V Gorbachev1, Hirohito Kobayashi, Daisuke Kudo, Charles S Tannenbaum, James H Finke, Suyu Shu, Joshua M Farber, Robert L Fairchild.   

Abstract

The role of tumor-produced chemokines in the growth of malignancies remains poorly understood. We retrieved an in vivo growing MCA205 fibrosarcoma and isolated tumor cell clones that produce both CXCL9/monokine induced by IFN-gamma (Mig) and CXCL10/IFN-gamma-inducible protein 10 following stimulation with IFN-gamma and clones that produce IFN-gamma-inducible protein 10 but not Mig. The Mig-deficient variants grew more aggressively as cutaneous tumors in wild-type mice than the Mig-producing tumor cells. The growth of Mig-expressing, but not Mig-deficient, tumor cells was suppressed by NK and T cell activity. Transduction of Mig-negative variants to generate constitutive tumor cell production of Mig resulted in T cell-dependent rejection of the tumors and in induction of protective tumor-specific CD8(+) T cell responses to Mig-deficient tumors. The results indicate a critical role for tumor-derived Mig in T cell-mediated responses to cutaneous fibrosarcomas and suggest the loss of Mig expression as a mechanism used by tumor cells to evade these responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277133     DOI: 10.4049/jimmunol.178.4.2278

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution.

Authors:  Huili Lu; Hongyu Liu; Jiaxian Wang; Jiaqing Shen; Shunyan Weng; Lei Han; Tao Sun; Lan Qian; Mingyuan Wu; Shunying Zhu; Yan Yu; Wei Han; Jianwei Zhu; Anja Moldenhauer
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-15       Impact factor: 4.553

Review 2.  Chemokine signaling in cancer-stroma communications.

Authors:  Arun J Singh; Joe W Gray
Journal:  J Cell Commun Signal       Date:  2021-06-04       Impact factor: 5.782

Review 3.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

4.  The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites.

Authors:  Yue-Qin Ai; Kai Cai; Jian-Hua Hu; Long-Wei Jiang; Yan-Rong Gao; Hua Zhao; Shao-Chang Jia
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 5.  Chemokines: can effector cells be redirected to the site of the tumor?

Authors:  Steven M Dubinett; Jay M Lee; Sherven Sharma; James J Mulé
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

6.  Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.

Authors:  Lynn T Dengel; Allison G Norrod; Briana L Gregory; Eleanor Clancy-Thompson; Marie D Burdick; Robert M Strieter; Craig L Slingluff; David W Mullins
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

Review 7.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

8.  Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.

Authors:  Joana Felix; Jérome Lambert; Marie Roelens; Eve Maubec; Hélène Guermouche; Cécile Pages; Irina Sidina; Debora J Cordeiro; Guitta Maki; François Chasset; Raphaël Porcher; Martine Bagot; Anne Caignard; Antoine Toubert; Céleste Lebbé; Hélène Moins-Teisserenc
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 9.  Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology.

Authors:  Richard M Ransohoff
Journal:  Immunity       Date:  2009-11-20       Impact factor: 31.745

Review 10.  Regulation of chemokine expression in the tumor microenvironment.

Authors:  Anton V Gorbachev; Robert L Fairchild
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.